Last reviewed · How we verify
Oxytocin 2 mIU/mL
Oxytocin 2 mIU/mL is a Oxytocin receptor agonist Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Induction or augmentation of labor, Control of postpartum hemorrhage, Promotion of milk letdown in lactation.
Oxytocin binds to oxytocin receptors on uterine smooth muscle and mammary gland tissue to stimulate contractions and milk ejection.
Oxytocin binds to oxytocin receptors on uterine smooth muscle and mammary gland tissue to stimulate contractions and milk ejection. Used for Induction or augmentation of labor, Control of postpartum hemorrhage, Promotion of milk letdown in lactation.
At a glance
| Generic name | Oxytocin 2 mIU/mL |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Oxytocin receptor agonist |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics and Gynecology |
| Phase | FDA-approved |
Mechanism of action
Oxytocin is a neurohypophyseal hormone that acts as an agonist at oxytocin receptors, G-protein coupled receptors present on myometrial cells and lactating breast tissue. Receptor activation triggers increased intracellular calcium, leading to smooth muscle contraction of the uterus during labor and milk letdown during lactation. It is also involved in social bonding and maternal behavior.
Approved indications
- Induction or augmentation of labor
- Control of postpartum hemorrhage
- Promotion of milk letdown in lactation
Common side effects
- Uterine hyperstimulation
- Nausea and vomiting
- Headache
- Hypertension
- Water intoxication (with prolonged high-dose infusion)
Key clinical trials
- Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour (PHASE4)
- Amniotomy for Second-trimester Pregnancy Termination (NA)
- Medical Management of Late Intrauterine Death. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytocin 2 mIU/mL CI brief — competitive landscape report
- Oxytocin 2 mIU/mL updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Oxytocin 2 mIU/mL
What is Oxytocin 2 mIU/mL?
How does Oxytocin 2 mIU/mL work?
What is Oxytocin 2 mIU/mL used for?
Who makes Oxytocin 2 mIU/mL?
What drug class is Oxytocin 2 mIU/mL in?
What development phase is Oxytocin 2 mIU/mL in?
What are the side effects of Oxytocin 2 mIU/mL?
What does Oxytocin 2 mIU/mL target?
Related
- Drug class: All Oxytocin receptor agonist drugs
- Target: All drugs targeting Oxytocin receptor (OXTR)
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Obstetrics and Gynecology
- Indication: Drugs for Induction or augmentation of labor
- Indication: Drugs for Control of postpartum hemorrhage
- Indication: Drugs for Promotion of milk letdown in lactation
- Compare: Oxytocin 2 mIU/mL vs similar drugs
- Pricing: Oxytocin 2 mIU/mL cost, discount & access